title: The potential interest of topiramate in addiction.
abstract: Topiramate is one of the currently most promising compounds in the field of addiction medicine. This paper discusses its potential utility related to a phase model of addiction development, focusing on the assumption that addiction is a continuous process involving different neurobiological pathways, depending on the stage of addiction. A specific emphasis will be made on the development of dysfunctional automatic behaviors in late stage of addiction and the central role of glutamate and AMPA receptors. The aim is to propose that if a too broad effect of anti-addiction medication is expected (such as anti-craving, anti-relapse and preventive effects), the results might be disappointing. The speculative specific efficacy of topiramate in addiction is described.
authors.affiliation: Division of Addictology, University Hospitals of Geneva, Switzerland. Gabriel.Thorens@hcuge.ch
authors.forename: Gabriel
authors.initials: G
authors.lastname: Thorens
authors.forename: Joel
authors.initials: J
authors.lastname: Billieux
authors.forename: Rita
authors.initials: R
authors.lastname: Manghi
authors.forename: Riaz
authors.initials: R
authors.lastname: Khan
authors.forename: Yasser
authors.initials: Y
authors.lastname: Khazaal
authors.forename: Daniele Fabio
authors.initials: DF
authors.lastname: Zullino
mesh_terms: D016739:Behavior, Addictive / Q000188:drug therapy; D016503:Drug Delivery Systems; D005632:Fructose / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D018698:Glutamic Acid / Q000378:metabolism; D006801:Humans; D008954:Models, Biological; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use; D018091:Receptors, AMPA / Q000378:metabolism; D055502:Secondary Prevention; D019966:Substance-Related Disorders / Q000188:drug therapy*; D000077236:Topiramate
chemical_list: D018696:Neuroprotective Agents; D018091:Receptors, AMPA; D000077236:Topiramate; D005632:Fructose; D018698:Glutamic Acid